Inhaled drug could offer new hope for lung scarring disease
NCT ID NCT07679893
First seen Jul 01, 2026 · Last updated Jul 24, 2026 · Updated 6 times
Summary
This phase 2 trial tests whether an inhaled form of nintedanib (MNKD-201) is safe and effective for people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring. About 210 adults with IPF will receive either a low or high dose of the inhaled drug or a placebo for 12 weeks, followed by a period where everyone gets the active drug. The study focuses on safety, especially breathing problems right after inhalation, and changes in lung function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Nintedanib dry powder inhalation
- What this could lead to
- If successful, this could offer a more targeted, inhaled treatment for IPF, potentially reducing side effects compared to the oral version.
- What could go wrong
- This is an early phase 2 trial with a small number of participants. The inhaled drug may cause bronchospasm or other side effects, and it may not prove effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Trial Management Group Inc
RECRUITINGWindsor, Ontario, N8X1T3, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill slow lung scarring in IPF?
- Beyond the lungs: the hidden emotional toll of IPF medications
- Can umbilical cord stem cells ease a scarring lung disease?
- Spotting hidden blood clots in scarred lungs: a study hunts for clues
- Can a new daily pill slow lung scarring in IPF?
- What makes someone stop a lung fibrosis drug? a study asks patients directly